

	M38 - KETOROLAC (TORADOL)	
	Version date: 2025-02-16	Effective date: 2025-04-30 (07:00)

INDICATIONS
<ul style="list-style-type: none"> Moderate to severe pain

WARNINGS
ABSOLUTE CONTRAINDICATIONS: <ul style="list-style-type: none"> Hypersensitivity to ketorolac History of aspirin-induced asthma or bronchospasm Active bleeding Intracranial injury Acute coronary syndrome (ACS)
USE WITH CAUTION: <ul style="list-style-type: none"> Pregnancy Known renal failure

ADMINISTRATION	
INTRAVENOUS (INTRAOSSEOUS)	PCP / ICP / ACP
ADULTS: <ul style="list-style-type: none"> Administer 30 mg by slow push over 60 seconds If time to medical care will be delayed, repeat every 4 to 6 hours as required INFANTS / CHILDREN / ADOLESCENTS: <ul style="list-style-type: none"> Administer 0.5 mg/kg by slow push over 60 seconds If time to medical care will be delayed, repeat every 4 to 6 hours as required 	
INTRAMUSCULAR	PCP / ICP / ACP
ADULTS: <ul style="list-style-type: none"> Administer 30 mg If time to medical care will be delayed, repeat every 4 to 6 hours as required CHILDREN / ADOLESCENTS: <ul style="list-style-type: none"> Administer 0.5 mg/kg If time to medical care will be delayed, repeat every 4 to 6 hours as required 	

NOTES
<ul style="list-style-type: none"> • None

LINKS
<ul style="list-style-type: none"> • None

APPROVED BY	
	
Provincial Medical Director	Provincial Associate Medical Director

VERSION CHANGES (refer to X08 for change tracking)
<ul style="list-style-type: none"> • Addition of advanced work scope • Revised contraindications & dosing